Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 Bioavailability and Food Effect Study
NCT05072535Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ha121-28 in non-small cell lung cancer (NSCLC) and medullary thyroid carcinoma (MTC) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Area under the concentration-time Curve from time zero to infinity, Area under the concentration-time curve from time zero to the last measurable concentration and 1 more. Started Oct 2021; status: completed.
02
Drugs
ha121-28
03
Conditions
non-small cell lung cancer (NSCLC)medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT05072535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072535.